New data support Boehringer's afatinib in Asian and non-Asian lung cancer patients

Data from two pivotal large-scale Phase III registration studies with German independent drug major Boehringer Ingelheim’s afatinib, LUX-Lung 3 and LUX-Lung 6, showed superior efficacy and a manageable safety profile in both Asian and non-Asian lung cancer patients compared to chemotherapy.

A new analysis of the trials has substantiated the consistent safety profile of afatinib as a first-line treatment in Asian and non-Asian patients with EGFR mutation positive non-small cell lung cancer (NSCLC).

The efficacy of afatinib is further reinforced by new data in NSCLC patient subpopulations. Additional analyses from the LUX-Lung trials demonstrate the efficacy of afatinib in NSCLC patients with uncommon EGFR mutations and those with metastatic brain disease.